Clinical trial
Randomized, Multicenter, 2-Dose Level. Open-Label, Phase IIa Study With the…
NCT00189345 · AGO Study Group, Other · Completed
Key facts
| NCT number | NCT00189345 |
|---|---|
| Title | Randomized, Multicenter, 2-Dose Level. Open-Label, Phase IIa Study With the Intraperitoneally Infused Trifunctional Bispecific Antibody Removab(TM) (Anti-EpCAM x Anti-CD3) to Select the Better Dose Level in Platinum Refractory Epithelial Ovarian Cancer Patients |
| Official title | Randomized, Multicenter, 2-Dose Level. Open-Label, Phase IIa Study With the Intraperitoneally Infused Trifunctional Bispecific Antibody Removab(TM) (Anti-EpCAM x Anti-CD3) to Select the Better Dose Level in Platinum Refractory Epithelial Ovarian Cancer Patients |
| Lead sponsor | AGO Study Group, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Ovarian Cancer, Fallopian Tube Neoplasms, Peritoneal Neoplasms |
| Intervention type | Biological |
| Interventions | anti-EpCAM x anti-CD3 (removab) |
| Enrollment | 44 |
| Start date | May 1, 2004 |
| Completion | Oct 1, 2005 |
| First posted | Sep 19, 2005 |
| Last update posted | Nov 8, 2006 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: